Rilpivirine for pediatric HIV-1 patients weighing 14–25 kg has received FDA approval.

Published Date: 24 Mar 2024

The indicated population may be administered the HIV-1 specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) using 25 mg oral tablets or the new 22.5 mg oral tablets, which were designed to facilitate administration and weight-adjusted dosing for children.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot